Inovio Pharmaceuticals' Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovio's Electroporation Delivery TechnologyMarch 14, 2011 12:32 am | by Bio-Medicine.Org | News | Comments
BLUE BELL, Pa., March 14, 2011 /- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its partner, ChronTech Pharma AB (formerly Tripep AB), has initiated a Phase...
Santarus Inc. stockholders weren't exactly hopping for joy after the U.S. Food and Drug Administration declined approval Feb. 26 of a product based on a new treatment for hereditary angioedema, or swelling of the face and airways, derived from rabbit's milk.
Life Technologies Corp. has joined a growing group of local biotech firms continuing to invest in Asia. The Carlsbad company announced that it has opened a 62,300-square-foot distribution center
(Wiley-Blackwell) Tamoxifen, taken by certain women as a preventive measure against breast cancer, saves lives and reduces medical costs. That is the conclusion of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. The study's results...
A Phase 3 clinical study of a type 1 diabetes treatment by Cambridge biotech Tolerx Inc., in conjunction with British pharmaceutical giant GlaxoSmithKline, failed to meet its primary endpoint.
Department of Energy announces funding to support the next generation of American scientists and engineersMarch 13, 2011 8:37 pm | by I-Micronews | News | Comments
Fellowship programs to support innovative research and ensure U.S. leadership in clean energy.
An engineered protein reduces arthritis symptoms in mice.
(DOE/Brookhaven National Laboratory) Scientists have demonstrated the efficacy of a "wearable," portable PET scanner they've developed for rats. The device will give neuroscientists a new tool for simultaneously studying brain function and behavior in fully awake, moving animals.
Hosts: Marc Pelletier and Vincent Racaniello How The Environment And A Single Protein Influence Evolution. Guests: Susan Lindquist, Ph.D. and Daniel Jarosz, Ph.D. We invite you to read, add to, and amend our show notes. Comments and suggestions on Futures in Biotech. Also thanks to Phil...
Covidien Receives FDA Approval for South African-Produced Medical Isotope Based on Low-Enriched UraniumMarch 11, 2011 4:34 pm | by Covidien | News | Comments
ST. LOUIS, Mar 10, 2011 (BUSINESS WIRE) --Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) has approved the use of molybdenum-99 (Mo-99) derived from low-enriched uranium (LEU) in the production of...
Heart valve maker Edwards Lifesciences Corp. said Friday that it has completed the purchase of Embrella Cardiovascular Inc. for $43 million in cash.Embrella developed a single-use disposable deflector system that can be used during heart procedures without blocking blood flow to the brain. The...
Joe Palca talks with researchers about how primates age, Americans' sleep problems, and the origins of the word 'clone.'
Joe Palca talks with researchers about seismology, taste sensation, and adding robots to a classic art form.
Manufacturers and importers of all devices must continue to submit malfunction reports as they await a promised easing of requirements for Class I devices and Class II devices that are not permanently implantable, life supporting or life sustaining.
Device manufacturers have won a victory in Congress now that the Senate has passed patent-reform legislation that includes several provisions favorable to the industry.